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Summary Puromycin-resistant (PurR) mutants/variants of a human carcinoma cell line (HeLa), which show
greatly reduced cellular uptake of 3H-puromycin and 3H-daunomycin have been isolated after one- and two-
step selections in presence of the drug. The cross-resistance pattern of these mutant cell lines towards
numerous anticancer drugs and other inhibitors has been examined. Both the first- and the second-step
mutants exhibited increased resistance to a number of antimitotic drugs (viz. vinblastine, vincristine,
colchicine, taxol and maytansine), several protein synthesis inhibitors (viz. chalcomycin, bruceantin, harring-
tonine, homoharringtonine), a large number of DNA interactive compounds (viz. aclacinomycin A, actin-
omycin D, adriamycin, m-AMSA, chromomycin A3, coralyne sulphoacetate, daunomycin, ellipticine,
mithramycin, mitoxantrone, 5-methoxysterigmatocystin, rubidazone, variamycin, VM26 and VP16-213) and a
number of other drugs acting via other mechanisms (viz. Baker's antifol, nitidine chloride and rhoda-
mine 123). Whereas the first-step mutants showed stable resistance to these drugs, the second-step lines
partially reverted upon growth in non-selective medium. Further, treatment of these mutant lines with non-
cytotoxic doses of the calcium channel blocker verapamil reverted or abolished their resistance to the above
drugs in a dose-dependent manner. In contrast to the above compounds, the PurR mutants showed no
significant cross-resistance to a large number of other drugs which included asaley, AT-125, 5-azacytidine,
azaserine, cyclocytidine, cis-platin, cytosine arabinoside, chlorambucil, chlorpromazine, a-difluoromethyl
ornithine, 5-fluorouracil, ftorafur, gallium nitrate, hydroxyurea, ICRF-159, ICRF-187, imipramine, metho-
traxate, 6-methylmercaptopurine riboside, mycophenolic acid, melphalan, mitomycin C, methyl GAG, nafoxi-
dine, reumycin, 6-selenoguanosine, 6-thioguanine, tiazofurin, tamoxifen, thalicarpine, tiapamil and verapamil).
These cross-resistance data should prove useful in developing suitable drug combinations to which cellular
resistance would not develop readily.
The development of resistance to chemotherapeutic drugs of
a tumour cell cell population is one of the major obstacles in
successful treatment of cancers. While some tumours may be
intrinsically resistant to drugs, a more common cause is
perceived to be the selection and expansion of a resistant cell
population, during the course of chemotherapy (Shoemaker
et al., 1983; Goldie & Coldman, 1984). To avoid develop-
ment of drug-resistance, a combination of drugs, acting at
different cellular targets and/or by different mechanisms, are
commonly employed in chemotherapy (Devita & Schein,
1973; Goldie et al., 1982). It is hoped that the cells resistant
to one drug will be killed by the other and that resistance to
the drug combination would not readily develop. However,
extensive studies with animals and cell culture model systems
during the past 15-20 years have revealed that in one of the
most commonly encountered mode of drug resistance,
resistance to multiple, structurally and functionally unrelated
drugs (e.g., vinblastine, vincristine, adriamycin, daunomy-
cin, actinomycin D, colchicine, puromycin, etc.) develops
readily and simultaneously (Dano, 1972; Skovsgaard, 1978;
Beidler et al., 1983; Ling et al., 1983; Akiyama et al., 1985;
Twentyman et al., 1986a; Beck, 1987). This multidrug-
resistance (MDR) phenotype underscores the fact that the
cross-resistance pattern of cells to various drugs cannot be
predicted a priori, based only on the information regarding
structures and/or mechanisms of action of drugs. Therefore,
in order to use the available anticancer drugs most effec-
tively, it is of much importance to experimentally obtain the
information regarding drug cross-resistance patterns, particu-
larly with the cells exhibiting MDR phenotype (Schabel et
al., 1983; Hill, 1984; Gupta, 1985; Twentyman et al., 1986b).
To obtain detailed information in this regard in a human
tumour cell line, puromycin resistant (PurR) mutants of
HeLa cells (a human cell line established from cervical
carcinoma) which exhibit MDR phenotype have been iso-
lated after one- and two-step selection in presence of the
drug. The cross-resistance pattern of the PurR mutants
towards a large number of anticancer drugs (both experi-
mental as well as those in current clinical use) is reported
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here. Further, effect of treatment of the mutant cells with
verapamil, a calcium channel blocker which has earlier been
reported to sensitize the drug resistant cells (Tsuruo et al.,
1981; Beck, 1984; Rogan et al., 1984; Twentyman et al.,
1986b), on the cellular resistance towards drugs has been
examined.
Materials and methods
Cell lines and culture conditions
HeLa (clone S3) and its drug-resistant variants were grown
routinely in monolayers in alpha MEM supplemented with
5% foetal bovine serum at 37°C in 95% air, 5% CO2
atmosphere (Singh & Gupta, 1985). Except where stated, the
cells were grown in the absence of any selective drugs.
Measurement of the degree of drug resistance
The degree of resistance of any cell line towards a given drug
was determined by seeding 100 and 250 cells of the parental
and the mutant cell lines in duplicate (in 0.5 ml of growth
medium) into the wells of 24-well tissue culture dishes
containing 0.5 ml of various drug dilutions made twice the
final concentrations desired in the growth medium. In most
of these experiments, 12 or more drug doses differing from
each other by a factor of 2 were employed. The drug doses
were chosen based on initial toxicity studies with the sensi-
tive and resistance cell lines and were such that the D1o value
(drug concentrations which reduced cloning efficiencies of
cells to 10%) of various cell lines lay within this range. The
sensitivity of both parental and mutant cell lines was deter-
mined in parallel in all of the experiments. The control cells
were treated with an equivalent amount of solvent in which
the drug was made.
Following the addition of cells, the dishes were incubated
for 8-10 days at 37°C in a CO2 incubator, after which they
were stained for -30min with 0.5% methylene blue in 50%
methanol. Subsequently the number of colonies (i.e., aggre-
gates having a colony morphology and containing >25 cells)
in each well was scored. From the average number of
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colonies observed in the presence of different drug concen-
trations, drug concentrations that reduced the relative plating
efficiencies (RPEs) of various cell lines to 10% of that
observed in the absence of any drug (i.e. D1o values) were
calculated. The degree of resistance of any cell line was
obtained from the ratios of the D1o values of the drug for
the mutant vs. the parental HeLa cell line. The degree of
resistance of all the mutant lines to various drugs have been
examined in at least 2 independent experiments which gave
very similar results. The repeat experiments were often
carried out with narrower spacing between the drug doses,
so that the degree of resistance could be more accurately
assessed.
Selection of mutants
Selection of mutants was carried out by procedures similar
to those employed earlier (Gupta, 1983a, b). Exponentially
growing HeLa cells were treated with 400 gml-1 of the
mutagen ethyl methanesulphonate (EMS) for 20 h. This
treatment results in about 50% cell killing (Gupta, 1983b).
The mutagen-treated cells were grown for 3 days in non-
selective medium to allow time for mutation fixation. The
selection of mutants was carried out by plating 1 x 106 cells
(mutagen-treated or control) per 100mm diameter dish, on
several dishes in medium containing the indicated concen-
trations of puromycin. The plating efficiencies of the cells at
the time of plating were determined by plating a known
number of cells in non-selective medium, and the observed
mutation frequencies were corrected for this.
Drugs and chemicals
AclacinomycinA, asaley, AT-125, m-AMSA [4'-(9-acridinyl-
amino) methanesulphon-m-anisidide], anguidine, Baker's
antifol, bisantrene, coralyne sulphoacetate, cyclocytidine,
ellipticine, ftorafur, gallium nitrate, harringtonine, homo-
harringtonine, ICRF-159, ICRF-187, maytansine, 5-
methoxysterigmatocystin (5-MSC), mitoxantrone, nafoxidine
chloride, nitidine chloride, reumycin, rubidazone, tamoxifen,
taxol, thalicarpine, tiazofurin, variamycin and VP16-213
were kindly provided by Dr V. L. Narayanan of the Drug
Synthesis and Chemistry Branch, National Cancer Institute,
Bethesda, MD. Mycophenolic acid and a-difluoro-
methylornithine (ac-DFMO) were generous gifts from Dr R.
L. Davis of Lilly Research Laboratories, Indianapolis, IN,
and Dr P. Bey, Centre de Recherche Merrell International,
Strasbourg, France, respectively. Actinomycin D, adriamycin,
5-azacytidine, azaserine, bleomycin, chalcomycin, chlor-
ambucil, chromomycin A3, colchicine, cytosine arabinoside,
daunomycin, 5-fluorouracil, hydroxyurea, imipramine, mel-
phalon, methotrexate, methyl GAG, 6-methylmercaptopurine
riboside (6-MEMPR), mithramycin, mitomycin C, pyromy-
cin, rhodamine 123, 6-selenoguanosine, tamoxifen, 6-
thioguanine, verapamil and vinblastine were purchased from
Sigma Chemical Co., St Louis, MO. VP16-213 and VM-26
were synthesized as described recently (Gupta et al., 1987).
Tiapamil hydrochloride was kindly provided by F. Hoff-
mann La Roche & Co., Basel, Switzerland. 3H-puromycin
dihydrochloride (specific activity 11 Ci mmol-1) and 3H-
daunomycin (specific activity 1.5 Ci mmol-1) were
purchased from Amersham Corp., Oakville, Ontario and
New England Nuclear, Boston, MA, respectively.
Cellular accumulation of labelled drugs
For studying the cellular accumulation of 3H-labelled drugs,
1 x 105 cells were seeded (in duplicate for each time
period) into the wells of 24-well tissue culture dishes. After
about 2 days, when the dishes were nearly confluent, the
medium was carefully aspirated, and 0.25ml of a solution
containing desired concentrations of the labelled drugs (3H-
puromycin, 1 x 10-9 M; 3H-daunomycin, 2 x 10-7 M) in
growth medium was added to each well. After 30min, the
labelled medium was removed, and cells were rinsed 3 times
with PBS. The cells from each well were dissolved in 0.25 ml
of a solution of 0.4% deoxycholic acid in 0.1 N NaOH, and
the amount of radioactivity was measured after the addition
of 3 to 4ml of aqueous counting scintillant (Amersham/
Searle Corp., Arlington Heights, IL). At the same time, total
numbers of cells in 2 parallel control wells of each cell line
were determined by trypsinization and the counting of
aliquots in a Coulter electronic counter. The cellular
accumulation of 3H-labelled drugs in different cell lines was
normalized for a constant cell number.
Results
The plating efficiency of HeLa cells in the presence of
puromycin decreases sharply in the concentration range of
0.05-0.15pugml-1 (Figure 1), and it becomes <lx10 at
0.2pgml- drug. The selection of resistant clones was
attempted in both mutagen (EMS)-treated and untreated
cells using 0.25pgml-1 puromycin. In the control cultures,
no resistant colonies were observed from a total of 1.6 x 107
viable cells (mutation frequency <6.3 x 10-8). However, in
the EMS-treated cultures, resistant colonies were obtained at
a frequency of -1 per 2 x 106 cells. The dose response curve
for puromycin for one of the clones (viz. PurRI27) which was
picked and grown in non-selective medium is shown
in Figure 1. Based on its D10 value for puromycin, this
mutant clone is 10-fold resistant in comparison to the
HeLa cells. A number of other clones which were similarly
examined showed lower degrees of resistance to puromycin
and were not investigated further. The drug-resistant pheno-
type of PurR127 is stably retained upon growth in non-
selective medium for more than one year.
The PurRI27 mutant was employed to select second-step
mutants (in presence of 10 gml-l puromycin) that exhib-
ited a higher degree of resistance to the drug. From EMS-
treated cultures, the second-step mutants were obtained at a
frequency of 1.4 x 10 -6 which was 10-fold higher than that
observed in non-mutagenized cells. Three individual second-
step colonies were picked and grown in medium containing
10lpgml-l puromycin. Based on their D1o values for puro-
mycin, these clones were between 80- to 130-fold more
resistant in comparison to the parental HeLa cells. The dose-
response curve for PurR17, which has been further investi-
gated is depicted in Figure 1.
Cellular accumulation of 3H-puromycin and 3H-daunomycin
by the parental and resistant cells
To determine if these mutants, similar to the other MDR-









Figure 1 Dose response curves of the parental and the mutant
cell lines towards puromycin. Q---Q =HeLa; 0---0 =
PurRI27; A---A =PurRII7.CROSS-RESISTANCE PATTERN OF MULTI-DRUG RESISTANT MUTANTS 443
(Dano, 1973; Cremisi et al., 1974; Inaba & Johnson, 1977;
Skovsgaard, 1978), accumulation of 3H-puromycin and 3H-
daunomycin in the parental and mutant cell lines was
investigated. From the results of these studies presented in
Table I, it is evident that in comparison to the parental
HeLa cells, intracellular levels of both drugs in the resistant
lines were much lower. Further, the second-step mutant
which exhibited higher degree of resistance to puromycin,
had lower intracellular drug levels, in comparison to the
PurRI27 line. The reduced intracellular levels of both 3H-
puromycin as well as 3H-daunomycin in the resistant cells
indicated that the genetic lesion in these mutants was similar
to that observed in other MDR mutants selected using other
anticancer drugs. The PurR variants of other mammalian cell
types (viz. mouse fibroblasts, pig kidney cells, Chinese
hamster V79 cells) which have earlier been reported (Lieber-
man & Ove, 1959; Cass, 1972; Morrow et al., 1980) also
showed reduced cellular accumulation of the drug.
Cross resistance pattern of the mutants towards other drugs
Earlier studies with mutants of Chinese hamster and human
cells selected for resistance to several anticancer drugs, e.g.
actinomycinD, daunomycin, vinblastine, vincristine, colchi-
cine, taxol, VM26, VP16, etc. show that they all exhibit cross
resistance towards puromycin (Biedler et al., 1983; Ling et
al., 1983; Gupta, 1983b; Hill, 1984; Akiyama et al., 1985;
Gupta, 1985; Meyers et al., 1985). In view of this and the
results of uptake studies, cross resistance pattern of the PurR
mutants towards a wide variety of anticancer drugs and
other inhibitors was examined. As expected, the PurR
mutants exhibited increased resistance towards a large
number of drugs (Table I), which included several antimito-
tic drugs (viz. colchicine, vinblastine, taxol and maytansine),
a large number of DNA intercalating and/or interacting
compounds (viz. aclacinomycin A, actinomycin D, adriamy-
cin, m-AMSA, chromomycin A3, coralyne sulphoacetate,
daunomycin, ellipticine, mithramycin, 5-MSC rubidazone,
variamycin, VM26 and VP16-213) and numerous other com-
pounds acting via other mechanisms. For all of these drugs
the second-step mutant PurRII7 exhibited higher degree of
resistance in comparison to the PurR127 line. However, in
contrast to the PurRI27 line whose resistance /cross-resistance
was completely stable in non-selective medium (this cell line
is routinely grown in non-selective medium), growth of
PurRII7 in puromycin-free medium led to either partial or
complete reversal of its drug-resistant phenotype (i.e., drop-
ping to a similar level as PurR127 from which it is derived by
a second-step selection).
In contrast to the drugs listed in Table II, the PurRI or
PurRII cell lines showed no cross-resistance towards a large
number of other drugs and inhibitors (Table III). These
drugs included various antimetabolites (AT-125, 5-
azacytidine, cyclocytidine, cytosine arabinoside (AraC), a-
DFMO, ftorafur, 5-fluorouracil, hydroxyurea, methotrexate,
6-methylmercaptopurine riboside (6-MeMPR), mycophenolic
acid, 6-selenoguanosine, 6-thioguanine), alkylating agents
(chlorambucil, melphalan, mitomycinC, ICRF-159, etc.) and
a large number of other drugs and inhibitors acting via other
Table I Cellular accumulation of 3H-puromycin and 3H-daunomycin
Accumulation of Accumulation
radioactivity relative to
Drug Cell line (pmol per 106 cells) HeLa cells
3H-Puromycin HeLa 1.30+0.32a 100
PurRl27 0.17+0.01 13.1
Purp"7 0.15+0.02 11.5
3H-Daunomycin HeLa 8.5 +0.14 100
PurR'27 2.8 +0.22 33.0
PurR`7 1.5 +0.15 17.6
The experiment was carried out as described in Materials and
methods. 'Means+s.d.
mechanisms (e.g., cis-platin, chloropromazine, ellipticine,
methyl GAG, reumycin, tiazofurin, tamoxifen, thalicarpine,
verapamil, etc.). It is noteworthy that the PurR mutants
showed no differences in sensitivity towards verapamil, to
which the vincristine-resistant mutants of Chinese hamster
cells have been reported to show enhanced sensitivity (Warr
et al., 1986).
Effects of verapamil on the drug-resistant phenotype
Recent studies from a number of different laboratories have
shown that treatment of MDR lines of human, mouse and
Chinese hamster cells with non-cytotoxic doses of verapamil
causes a partial or complete reversal of the drug-resistance
phenotype (Tsuruo et al., 1981; Slater et al., 1982; Beck,
1984; Kessel & Wilberding, 1985; Twentyman et al.,
1986a, b; Warr et al., 1986). In view of this, it was of interest
to examine the effect of verapamil treatment on the degree
of resistance of the PurR mutants for a number of different
drugs. As indicated earlier, the sensitivity of verapamil for
the parental HeLa cells, as well as the PurR mutants was
very similar, and the Di0 value of the drug was
-30ygml-1. However, verapamil, at concentrations up to
15ugml-1, had no cytotoxic or growth inhibitory effect on
any of the above cell lines.
Table IV presents the results of our studies on examining
the effect of non-cytotoxic concentrations of verapamil on
the drug-sensitivity of the parental and resistant cell lines.
Treatment with 10jugml-l verapamil had a very marked
effect on the level of resistance of the PurR line towards
various drugs but had no effect on the drug sensitivity of the
HeLa cell lines. For all of the drugs examined (viz. puromy-
cin, taxol, actinomycin D, vinblastine, daunomycin, mitoxan-
trone, bisantrene, VP16), nearly complete reversal of drug-
resistance was noted at lOgml-l verapamil. Further, as
shown for puromycin and taxol, the extent of reversal of
drug-resistance was directly related to the concentration of
verapamil in the growth medium. For both puromycin and
taxol at 1 and 3 gml-1 verapamil, only partial reversal of
drug-resistance for the PurR mutants was observed.
Discussion
This paper describes the selection and detailed cross-
resistance pattern of mutants of HeLa cells resistant to the
protein synthesis inhibitor puromycin. The PurR mutants
described here showed much lower accumulation of 3H-
labelled drugs, which correlated with the level of resistance
of the mutant cells. Further, these mutants exhibit high
levels of cross-resistance to a wide variety of structurally and
functionally unrelated compounds. Based on these character-
istics, the genetic lesion in these mutants should be similar to
that observed in other multidrug-resistant cell lines selected
for resistance to other drugs, such as vinblastine, vincristine,
adriamycin, daunomycin, actinomycin D, colchicine, taxol,
etc. (Dano, 1972; Skovsgaard, 1978; Biedler et al., 1983;
Gupta, 1983b; Ling et al., 1983; Akiyama et al., 1985;
Gupta, 1985). The biochemical basis of MDR in Chinese
hamster, mouse leukaemia and human leukaemia and KB
cells has been extensively studied in recent years. These
studies indicate that multiple factors could contribute to the
development of MDR phenotype (Riordan & Ling, 1985;
Beck, 1987). These include (i) decreased rate of drug uptake
or influx; (ii) enhanced active efflux or transport of the
drugs, and (iii) altered/reduced intracellular binding of the
drug(s). In addition, the cell lines exhibiting high levels of
MDR most frequently show increased expression of a family
of cell surface glycoproteins (commonly referred to as P
glycoproteins), which results from amplification of the cor-
responding genes (Ling et al., 1983; Roninson et al., 1984;
Meyers et al., 1985; Riordan et al., 1985; Ames, 1986; Gros
et al., 1986; Beck, 1987). Although our preliminary studies
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Table II Anticancer drugs exhibiting cross-resistance to the PurR mutants
Di0 value
for HeLa Relative degree of resistance"
cells'
Drug NSC no. (Mgml ') HeLa PurR'27 PurR1I7 PurRII7c
Aclacinomycin A 208734 0.002 1 2.5 10.0 2.5
Actinomyhcin D 3053 0.00008 1 15.0 150.0 35.0
Adriamycin 123127 0.005 1 6.0 80.0 6.0
m-AMSA 141549 0.015 1 2.0 n.d. 2.0
Bisantrene 337766 0.001 1 7.0 24.0 10.0
Baker's antifol 139105 0.05 1 >10.0 n.d. >10.0
Chalcomycin - 0.006 1 1.5 n.d. 2.0
Chromomycin A3 58514 0.007 1 8.0 n.d. 12.5
Colchicine - 0.002 1 8.0 100.0 20.0
Coralyne sulphoacetate 154890 0.002 1 4.0 n.d. 4.0
Daunomycin 82151 0.004 1 10.0 105.0 12.0
Ellipticine 71795 0.06 1 1.4 n.d. 2.0
Harringtonine 124147 0.035 1 4.5 30.0 8.0
Homoharringtonine 141633 0.02 1 4.0 n.d. 5.0
Maytansine 153858 0.00005 1 5.0 60.0 33.0
Mithramycin 24559 0.02 1 8.5 26.0 15.7
Mitoxantrone 301739 0.01 1 60.0 480.0 100.0
5-MSC 178249 0.7 1 3.0 n.d. 3.0
Nitidine chloride 146397 0.001 1 12.0 n.d. 64.0
Puromycin - 0.1 1 12.0 120.0 50.0
Rhodamine 123 - 1.2 1 65.0 n.d. 75.0
Rubidazone 164011 0.005 1 8.5 n.d. 13.0
Vinblastine 49482 0.0007 1 11.5 100.0 >20.0
Vincristine 67574 0.0015 1 10.0 n.d. 15.0
Variamycin 269146 1.2 1 12.0 n.d. 25.0
VM26 122819 0.01 1 4.5 50.0 10.0
VP16-213 141540 0.1 1 8.0 45.0 16.5
Taxol 125973 0.0015 1 25.0 200.0 35.0
aThe Dlo value represents the concentration of the drug which reduces plating efficiency of
a cell line to 10% of that observed in the absence of any drug. The D1o values of various
drugs for the HeLa and the mutant cell lines were obtained from experiments similar to
those described in Figure 1. Similar results (±10%) with these cell lines have been obtained
in at least 2 independent experiments. bAssuming the D1o values of various drugs toward
HeLa cells as 1, the relative degrees of resistance of the mutant cell lines were obtained from
the ratios of the D1o values of the mutant cell lines and the HeLa cells. CThe PurR`7 cells
which are maintained in medium containing 10pgml-1 puromycin were grown for 3 weeks
in the absence of puromycin before these experiments were carried out. The resistance
pattern of PurRI27 is completely stable and is unaffected under these conditions.
employing a monoclonal antibody for the P-glycoprotein
(kindly provided by Dr V. Ling, Ontario Cancer Institute)
have failed to detect increased expression of this protein in
these mutants (unpublished results) this may be due to the
relatively low level of resistance of these mutant cells. To
clarify this aspect, further studies using cloned cDNA probes
for the MDR gene are being carried out.
The main emphasis of the current work, however, was on
examining in detail the cross-resistance pattern of a human
MDR cell line towards various anticancer drugs. In the past,
only limited studies in this regard with the human MDR cell
lines have been reported (Beck, 1983; Akiyama et al., 1985;
Twentyman et al., 1986a, b). For many of the drugs
employed in the present investigation (viz. Baker's antifol,
chalcomycin, coralyne sulphoacetate, harringtonine, homo-
harringtonine, tamoxifen, reumycin and thalicarpine, etc.),
the cross-resistance of the MDR cell line has been examined
for the first time. Based on the cross-resistance pattern of the
PurR mutants, the drugs which have been examined could be
divided into two groups: those to which the MDR mutants
exhibit increased resistance (Table II) and the others for
which no significant change in resistance is observed (Table
III). The former group includes a number of antimitotic
drugs (viz. colchicine, taxol, maytansine, vinblastine, vincris-
tine), a few protein synthesis inhibitors (viz. puromycin,
chalcomycin, harringtonine, homoharringtonine, bruceantin),
several compounds which either directly bind or intercalate
into DNA (viz. aclacinomycin A, actinomycin D, adriamycin,
m-AMSA, chromomycinA3, coralyne sulphoacetate, dauno-
mycin, ellipticine, mithramycin, mitoxantrone, 5-MSC,
nitidine chloride, rubidazone, variamycin, VM26 and VP16-
213). A few other drugs to which the PurR mutants exhibit
cross-resistance (viz. rhodamine 123, Baker's antifol) may act
via other mechanisms.
In an earlier study the cross resistance pattern of single-
step mutants of Chinese hamster ovary (CHO) cells selected
for resistance to either vinblastine or taxol to a large number
of these drugs was examined (Gupta, 1985). A comparison
of the results of these two studies indicates that the cross
resistance patterns of these independently selected mutants
resistant to various drugs (viz. taxol, vinblastine and puro-
mycin) in cells of two different species, are virtually identical.
The pattern observed here is also in accordance with the
results of limited cross resistance studies carried out with
various other MDR cell lines of different species reported in
the literature (Dano, 1972; Skovsgaard, 1981; Beck, 1983;
Biedler et al., 1983; Ling et al., 1983; Akiyama et al., 1985;
Twentyman et al., 1986). These results provide strong evi-
dence that the MDR mutants of different species exhibit
increased resistance to the same specific group of drugs,
listed in Table I.
The results presented in this paper have a number of
important implications regarding clinical applications of anti-
neoplastic drugs. Our studies provide evidence that mutants
exhibiting MDR phenotype could be obtained in human cells
after a single-step selection and that multiple selection or
prolonged growth in selective medium is not necessary for
generation of this phenotype. Although the frequency of
resistant mutants in control HeLa cell population is low
(<1X 10-7) in a tumour that contains a large number of
target cells (_ 108 or more), the resistant cells may pre-exist
and their growth will be selectively enhanced in the presenceCROSS-RESISTANCE PATTERN OF MULTI-DRUG RESISTANT MUTANTS 445
Table III Anticancer drugs to which PurR mutants do not show cross resistance
D1o value Relative degree of
for HeLa resistance"
cells
Drug NSC no. (pgml-1) HeLa PurRI27 PurRII7
Anguidine 141537 0.006 1 1.0 0.8
Asaley 167780 0.004 1 1.0 1.0
AT-125 163501 0.15 1 0.7 0.8
5-Azacytidine 102816 0.12 1 0.6 0.6
Azaserine - 0.05 1 1.0 1.0
Bleomycin 125066 5.0 1 1.0 1.0
Chlorambucil 3088 7.0 1 1.0 0.8
Chlorpromazine - 3.5 1 1.0 1.0
Cis-platin 119875 0.3 1 1.0 0.8
Cyclocytidine 145668 0.01 1 1.0 0.7
Cytosine arabinoside 63878 0.025 1 1.0 0.8
a-DFMO - 5.0 1 0.8 0.8
5-Fluorouracil 19893 0.2 1 1.0 1.0
Ftorafur 148958 4.0 1 1.0 1.0
Gallium nitrate 15200 7.5 1 1.0 1.0
Hydroxyurea 32065 12.5 1 1.0 1.0
ICRF-159 129943 35.0 1 1.0 1.0
ICRF-187 169780 30.0 1 1.0 1.0
Impiramine - 15.0 1 1.0 1.0
Melphalan 8806 10.0 1 1.0 1.0
6-MeMPR - 0.008 1 1.0 1.0
Methotrexate 740 0.007 1 1.0 1.0
Mitomycin C 26980 0.015 1 1.6 1.5
Methyl GAG 32946 0.15 1 1.0 1.0
Mycophenolic acid - 0.05 1 0.8 1.0
Nafoxidine HCl 70735 2.0 1 1.0 1.0
Reumycin 99733 50.0 1 1.0 1.0
6-Selenoguanosine 137679 0.25 1 1.0 1.0
Tamoxifen 180973 4.0 1 1.0 1.0
Thalicarpine 68075 7.0 1 1.0 1.0
6-Thioguanine 752 0.03 1 1.0 1.0
Tiapamil - 50.0 1 1.0 1.0
Tiazofurin 286193 2.5 1 1.0 1.0
Verapamil - 25.0 1 1.0 1.0
'The relative resistances of the mutant cell lines as compared to the parental
HeLa cells were determined as described in Table H.

































Di0 values for the cell lines
(ml-1)
HeLa PurRI27 PurR"7
0.12 pg 1.2 ug 5.5 jig
0.11 mg 0.45 pg 2.5 pg.
0.12 pg 0.30 pg 0.40 pg
0.11 pg 0.12 pg 0.15 pg
2.0 ng 50.0 ng 70.0 ng
2.0 ng 15.0 ng 20.0 ng
2.0 ng 7.0 ng 8.0 ng
1.8 ng 3.0 ng 3.5 ng
0.08 ng 1.2 ng 2.6 ng
0.05 ng 0.05 ng 0.06 ng
1.5 ng 10.0 ng 14.0 ng
1.5 ng 1.5 ng 1.5 ng
4.0 ng 40.0 ng n.d.
3.5 ng 4.0 ng n.d.
15.0 ng 1000 ng 2000 ng
15.0 ng 30.0 ng 40.0 ng
1.0 ng 10.0 ng 20.0 ng
0.4 ng 0.4 ng 0.6 ng
0.10 pg 1.1 pg 1.8 yg
0.10 pg 0.13 pg 0.2 pg
of the selective drugs. Since many of the antineoplastic drugs
are mutagenic (Singh & Gupta, 1983), treatment with such
drugs may result in both induction as well as selective
growth of the resistant cells. In accordance with this expec-
tation, cells exhibiting cross resistance to a variety of drugs
have been reported in human tumour cell populations (Bech
Hansen et al., 1977; Shoemaker et al., 1983). Recently,
increased expression of P-glycoprotein or of the correspond-
ing gene, in a number of human tumours which are refrac-
tory to chemotherapy, has also been reported (Bell et al.,
1985; Gerlach et al., 1986; Fojo et al., 1987). The obser-
vation that all of the refractory tumours do not show
increased expression of the P-glycoprotein may be related to
the lower degree of resistance of such tumours, similar to
that seen with the present mutants.
Asssuming that the cells exhibiting MDR phenotype may
either pre-exist or are readily induced/selected in a tumour
cell population, and are the major impediment in the success
of chemotherapy, two possible strategies could be employed
to overcome clinical resistance. First, based on the cross
resistance information regarding such mutants, more effec-
tive drug combinations to which cellular resistance would
not readily develop (i.e., in a single selection step) could be
formulated. Such a combination should include no more
than one drug from the first group (listed in Table II, to
which resistance develops simultaneously) and one or more
agents from the second group (Table III), to which the
mutants exhibiting MDR phenotype do not show increased
resistance. Interestingly, the MDR mutants exhibit margin-
ally enhanced sensitivity to a number of agents in the latter
The D1o values (given in either pgml 1 or ngml-') of the cell
lines for various drugs were determined in parallel in presence of
either the solvent control (i.e., 0 verapamil) or the indicated
concentrations of verapamil. n.d.=not determined.446 R.S.GUPTA et al.
group (viz. AT-125, 5-azacytidine, a-DFMO; Table III), and
the use of these drugs in combination with the first group of
drugs may prove particularly effective in preventing the
emergence of MDR cells. The second strategy to overcome
drug resistance should make use of the observation that the
MDR phenotype of human cells is completely reversed in the
presence of agents such as verapamil. Besides verapamil, a
large number of other compounds (e.g., reserpine, quinidine,
trifluoperazine, chlorpromazine, chloroquine, etc.) have been
reported to cause reversal of the MDR phenotype (Inaba et
al., 1981; Tsuruo et al., 1981, 1984; Ganpathi & Grabowski,
1983; Beck, 1984; Akiyama et al., 1988). Although the
mechanism by which these compounds cause reversal of the
MDR is unclear at present, the use of one of these agents in
combination with the drugs listed in Table I should enhance
the chemotherapeutic effectiveness of the latter drugs. Based
on the above considerations, more effective chemo-
therapeutic drug combinations in principle could be obtained
by combining the above two strategies, i.e., employing a
drug from the first group (Table II) in conjunction with an
agent which overcomes MDR and one or more drugs from
the second group (Table III), to which the MDR mutants do
not exhibit cross resistance.
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